PT-141 10mg

1 Vial PT-141 10mg lyophilized powder

For More Information Click Here

PT-141 (Bremelanotide)

Clinical data
Pronunciation	/ˌbrɛmɪˈlænətaɪd/ ⓘ
Other names	PT-141; Rekynda, bremelanotide acetate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a619054
License data	US DailyMed: Bremelanotide
Routes of administration	Subcutaneous[1]
Drug class	Central nervous system agent
ATC code	G02CX05 (WHO)
Pharmacokinetic data
Bioavailability	SCTooltip Subcutaneous injection: ~100%[1]
Protein binding	21%[1]
Metabolism	Hydrolysis of peptide bonds[1]
Elimination half-life	2.7 hours[1]
Excretion	Urine: 64.8% Feces: 22.8%
Identifiers
show IUPAC name
CAS Number	189691-06-3
PubChem CID	9941379
DrugBank	DB11653
ChemSpider	8116997
UNII	6Y24O4F92S
KEGG	D06569
ChEMBL	ChEMBL2070241
CompTox Dashboard (EPA)	DTXSID40893711
Chemical and physical data
Formula	C50H68N14O10
Molar mass	1025.182 g·mol−1
3D model (JSmol)	Interactive image
show SMILES
show InChI
(verify)

**The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. Additionally, it is important to note that research chemicals are intended solely for laboratory study by professional researchers and are not intended for human consumption.**